About
About Bioheng
History
Science & Products
Pipelines
Technology Platforms
Publications
Patients
Expanded access
News
Event Highlights
Contact
Investor Relations&BD
25
2025-11
Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
30
2025-10
Imviva Biotech Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for CTD402 in Relapsed/Refractory T-ALL/LBL
Imviva Biotech Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA313 for Patients with Autoimmune Diseases at ACR Convergence 2025
28
ACR 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Allogeneic CAR-T Therapy CTA311 and CTA313 for Patients with Autoimmune Diseases
16
2025-06
EHA 2025 | Bioheng Therapeutics Presents Latest Clinical Data on Universal CAR-T Therapy CTD402 for Patients with R/R T-ALL/LBL
Contact Us
Consult Now
